Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

Cancer Chemother Pharmacol. 2008 May;61(6):903-9. doi: 10.1007/s00280-008-0711-0. Epub 2008 Mar 4.


Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).

Publication types

  • Guideline
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cisplatin / adverse effects*
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Humans
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / prevention & control*
  • Neoplasms / complications
  • Neoplasms / drug therapy


  • Antineoplastic Agents
  • Cisplatin